Partnering plays a key role in Agennix’s strategy.

Agennix is focused on developing novel therapies that have the potential to substantially to improve the length and quality of life of critically ill patients in areas of major unmet medical need.

The Company is focused on pharmaceutical companies and large biotechnology firms with a strong presence in the area of critical care and/or cancer development and commercialization.

For further information on Agennix’s approach to partnering and current opportunities, please contact:

Business Development